About us
London based specialist corporate advisory firm, established 2003 focusing on health and climate change related technology innovation:
  • Corporate finance and M&A
  • Sovereign, strategic, professional and family investors
  • IP, business & corporate development advisory

Our mission is to assist IP rich private & public companies with finding the right investors, acquirers, customers, licensees and commercial partners; and to help them adapt to policy frameworks in different geographies.

We are acutely aware of the limited time management have for non-operational activities and the importance of R&D and commercial plan execution.

We source exceptional, disruptive technologies from >600 candidates per annum – the best are selected also to present at our CleanEquity® conference.

Our services
Corporate finance and M&A
Our core competence is founded on more than 40 years of experience, which extends into licensing, joint venture and joint development agreements
Sovereign, strategic, professional and family investors
The key to success in corporate finance is choosing the right financial partner - we cover the global spectrum, client's interests come first
IP, business & corporate development advisory
We understand the R&D process and ensure that our clients implement an IP strategy for optimum outcomes with future partners
Team
  • Team
  • CleanEquity
  • Committee
Mungo Park
Chair & Founder
Mungo Park
Chair & Founder
- 40+ years investment banking, sustainable technologies, life sciences & ICT
- Previous Non-Executive Director, CDTI - NASDQ listed Materials Sciences
- CleanEquity® Monaco co-Founder with H.S.H. Prince Albert II of Monaco
- Adviser CCF, UK Minister of State, Dept. Energy & Climate Change
Veronika Kasparova
Director, Corporate Finance
Veronika Kasparova
Director, Corporate Finance
- MSc. in Russian & East European Studies, University of Oxford
- Background in International Political Economy, Univ. of Westminster
- Prev. healthcare research analyst at Kaiser Associates
- NGO, Community Service Volunteers, social impact

CleanEquity®
His Serene Highness Prince Albert II of Monaco & Mungo Park, Chairman of Innovator Capital, founded CleanEquity® Monaco in 2008 to accelerate next generation disruptive sustainable technologies from all over the world.

The Conference provides these technology companies an intimate and collegiate setting to connect with selected sovereign, corporate, family and professional investors & acquires, policy makers, end users and international trade media.

Delegates are a select group of senior representatives of their respective organisations – this ensures a high value contribution to the conference. The tried and tested format assures effective use of time in ideal surroundings.

CleanEquity’s purpose is to help companies springboard to their next stage of development. Presenting companies have since gone on to raise almost $2bn.

Observe
  • Disruptive technologies
  • Revolutionary market dynamics
  • Multi-sector coverage
Network
  • Leading international investors
  • Environmental experts & global decision makers
  • Exchange intelligence and develop business relationships & partnerships
Listen
  • Knowledgeable & distinguished speakers
  • Specialist cleantech funds & multinational strategic investors
  • World alternative energy policy influencers
Participate
  • Plenary sessions, workshops & technology showcases
  • The CEO & Gala Dinners - with placement
  • Pre arranged and on the spot 1 to 1 meetings
Visit the CleanEquity website
Sustainable Finance & Innovation Co-operation (SFIC)
SFIC's mission is to enable all participating countries to achieve Article 10 of the Paris Climate Agreement and for those technologies to transform our collective ability to reach net zero greenhouse gases by 2050.
SFIC will service sovereign funds, multi-lateral development banks/funds (MDB/MLFs) and direct finance institutions from three divisions:
  • Corporate Finance & Advisory
  • Research & Impact
  • Events
The strategy is in line with each countries Nationally Determined Contributions (NDCs) Sustainable Development Goals (SDGs) commitments and target the Climate Health Nexus. Themes will focus specifically on:
  • Climate Mitigation: Technologies capable of avoiding or sequestering CO2e
  • Adaptation and Resilience: Technologies capable of increasing country level preparedness for the impacts of climate change
  • Climate related Health Impacts: The health and wellbeing of each country, that could either impact or be impacted by climate change
Track record (sample)
Offering customers end-to-end energy services, including energy insights, demand management and on-site generation
REstore
  • CleanEquity® 2014 & 10th Anniv. Winner
  • ICL was exclusive advisor on €7.5m Series C
  • Subsequently acquired by Centrica €70m in 2017
Developing insect-based protein products, opening the world’s first industrial scale insect recycling site in 2016
AgriProtein
  • CleanEquity® 2017 (Winner) & 2018
  • Subsequently raised $105m in 2018
Reliable, efficient liquid cooling technology for every possible application, cooling any hardware in any environment
Iceotope
  • CleanEquity® 2013 & 2017 (Winner)
  • ICL advised on $10m raise in 2013;
  • and raised additional $8m in 2018
Developing and commercialising next generation nuclear fuel technology
Lightbridge
  • CleanEquity® 2016 (Winner), 2017 & 2018
  • LTBR has secured ~$30m investment since 2018
  • LTBR are advised by ICL
Empowering innovators through its crop design platform, CropOS, to create healthier, more sustainable food and ingredients
Benson Hill Biosystems
  • CleanEquity® 2017
  • Subsequently raised $25m Series B
  • plus $60m in 2018 led by GV, & $32m in 2019
Developed a set of unique chemical process technologies for converting renewable feedstocks into high-value, specialty chemicals, including flavour and fragrance ingredients
P2 Science
  • CleanEquity® 2019
  • ICL advised on $12m Series C,
  • with HG Ventures, CHANEL, BASF & Xeraya
Developing a pipeline of products for the treatment of various cancers
SapVax
  • ICL advised on undisclosed amount funding; and
  • Licensing to BioMotiv in the USA
  • Transaction closed in 2017
Developing drugs to treat heart failure for hypertrophic cardiomyopathy patients
HeartMetabolics
  • ICL assisted HeartMetabolics raising $4m
  • HMB was acquired subsequently
Objective vision screening primarily for children under the age of 6 for early detection of vision disorders
Objective Acuity
  • ICL advised OAL on a collaboration agreement
  • with China's leading eye care hospital network
Developing powertrain electrification, hybridisation and connectivity technologies for heavy-duty vehicles around the world
Vantage Power
  • CleanEquity® 2014 & 2016 (Runner Up)
  • Advised by ICL raised £2.5m in 2017 for London's
  • first triple axle hybrid bus launch in 2018
Network of family dentists across Scotland
Clyde Munro Dental Group
  • ICL advised on the buy-in management buyout
  • with capital provided by Synova Capital
Wireless charging technology for electric vehicles
HaloIPT
  • CleanEquity® 2011
  • ICL managed Arup taking a 25% stake
  • before managing the acquisition from Qualcomm
Contact details
Innovator Capital

Office 307, 20 Mortlake, Mortlake High Street

London, SW14 8JN


+44 20 7297 6840

info@innovator-capital.com
Directions